Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

INSIGHT-IBD Pragmatic Study

28 de outubro de 2026 atualizado por: Specialty Networks Research.

INSIGHT-IBD Pragmatic Study: Investigation of Mirikizumab in Real World Settings for Mirikizumab

The goal of this study is to evaluate the real-world effectiveness of treatments for inflammatory bowel disease (IBD) within routine clinical practice.

The study population includes adult patients (≥21 years) with ulcerative colitis (UC) or Crohn's disease (CD) receiving care in community gastroenterology practices in the United States.

The main questions it aims to answer are:

  • Does treatment with mirikizumab reduce the proportion of patients requiring an increase in IBD disease management (e.g., unplanned visits, dose escalation, therapy switch, emergency department visits, or hospitalization)?
  • Does treatment with mirikizumab improve clinical outcomes, including disease activity, clinical remission, and patient-reported outcomes, compared to standard biologic therapy?
  • Researchers will compare patients treated with mirikizumab within the IBD Clinical Care Pathway versus patients receiving standard biologic therapies to see if mirikizumab leads to improved disease control and reduced healthcare utilization.

Participants will:

  • Receive either mirikizumab or standard biologic therapy as part of routine clinical care
  • Attend follow-up visits at approximately 3, 6, 12, and 18 months
  • Have clinical data collected from electronic health records and healthcare utilization sources
  • Complete patient-reported outcome questionnaires assessing symptoms, quality of life, and daily functioning
  • Undergo routine laboratory tests and clinical assessments as part of standard care

Visão geral do estudo

Status

Inscrevendo-se por convite

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

400

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Arizona
      • Sun City, Arizona, Estados Unidos, 85351
        • Arizona Digestive Health
      • Tucson, Arizona, Estados Unidos, 85704
        • AZ Digestive Health-Tucson
    • Illinois
      • Glenview, Illinois, Estados Unidos, 60005
        • GI Alliance of Illinois
      • Gurnee, Illinois, Estados Unidos, 60031
        • Lake Shore Gastro-Gurnee Research
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46237
        • Indianapolis Gastroenterology & Hepatology
    • New York
      • Rochester, New York, Estados Unidos, 14618
        • Gastroenterology Group of Rochester
    • Texas
      • Cedar Park, Texas, Estados Unidos, 78613
        • Texas Digestive Disease Consultants
      • Fort Worth, Texas, Estados Unidos, 76104
        • Texas Digestive Disease Consultants
      • Houston, Texas, Estados Unidos, 77024
        • Digestive Health Associates
      • Plano, Texas, Estados Unidos, 75093
        • Texas Digestive Disease Consultants: Plano
      • San Antonio, Texas, Estados Unidos, 78215
        • Texas Digestive Disease Consultants: San Antonio
      • San Marcos, Texas, Estados Unidos, 78666
        • Texas Digestive Disease Consultants: San Marcos
    • Virginia
      • Richmond, Virginia, Estados Unidos, 23229
        • GI Alliance Richmond

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

21 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age ≥21 years at the time of enrollment
  • Confirmed diagnosis of ulcerative colitis (UC) or Crohn's disease (CD)
  • Eligible for treatment with biologic therapy for IBD, as per the IBD Clinical Care Pathway
  • No prior exposure to mirikizumab and no contraindications to mirikizumab
  • Ability to provide informed consent
  • Willingness to comply with study procedures and follow-up requirements

Exclusion Criteria:

  • Prior exposure to IL-23p19 antagonists (e.g., mirikizumab, risankizumab, guselkumab)
  • Prior exposure to small molecule targeted therapies for IBD (e.g., JAK inhibitors or S1P receptor modulators)
  • Participation in an interventional clinical trial within 90 days prior to enrollment
  • History of extensive colorectal resection, including:
  • Total proctocolectomy (for UC), or
  • Surgical removal of two or more intestinal segments (for CD)
  • Any condition that, in the investigator's judgment, may compromise patient safety, data integrity, or ability to participate in the study

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Pesquisa de serviços de saúde
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Mirikizumab Clinical Care Pathway

Participants receive mirikizumab as part of the IBD Clinical Care Pathway in routine clinical practice. Dosing and administration follow the approved prescribing information for ulcerative colitis or Crohn's disease, with treatment and monitoring per standard of care.

Mirikizumab administered according to approved dosing regimens for ulcerative colitis and Crohn's disease.

Comparador Ativo: Standard Biologic Therapy Clinical Care Pathway

Participants receive standard biologic therapies for IBD as part of the IBD Clinical Care Pathway according to physician discretion and routine clinical practice. Therapies may include anti-TNF agents, anti-integrins, IL-12/23 antagonists, or IL-23p19 antagonists.

Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.

Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.

Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.

Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Proportion of Patients Requiring an Increase in IBD Disease Management
Prazo: Up to 18 months following initiation of therapy

The proportion of patients requiring an increase in inflammatory bowel disease (IBD) disease management, defined as a composite of treatment and healthcare resource use, while receiving index therapy.

Up to 18 months following initiation of therapy

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in Disease Activity Measured by Crohn's Disease PRO2 Scores
Prazo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in disease activity assessed using validated patient-reported outcome measures:

Crohn's Disease Patient-Reported Outcome 2 (CD PRO2), composed of:

Abdominal pain score (range 0-3) Stool frequency (number of bowel movements per day; higher values indicate worse disease activity)

Changes in PRO2 component scores and composite disease activity will be evaluated over time, with decreases from baseline indicating improvement in disease activity.

Baseline, 6 months, 12 months, and 18 months
Change in Disease Activity Measured by Ulcerative Colitis PRO2 Scores
Prazo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in disease activity assessed using validated patient-reported outcome measures:

Ulcerative Colitis Patient-Reported Outcome 2 (UC PRO2), composed of:

Stool frequency score (range 0-3) Rectal bleeding score (range 0-3) Total possible combined score range: 0-6, with higher scores indicating worse disease activity

Changes in PRO2 component scores and composite disease activity will be evaluated over time, with decreases from baseline indicating improvement in disease activity.

Baseline, 6 months, 12 months, and 18 months
Proportion of Participants Achieving Endoscopic Remission Measured by Simple Endoscopic Score for Crohn's Disease (SES-CD)
Prazo: Up to 18 months (as available from routine clinical care)

Proportion of participants achieving endoscopic remission assessed using validated endoscopic scoring system:

Simple Endoscopic Score for Crohn's Disease (SES-CD) (range 0-56), where lower scores indicate less endoscopic disease activity and endoscopic remission is defined as a score ≤2

Endoscopic findings are collected as part of routine clinical care, when available.

Up to 18 months (as available from routine clinical care)
Proportion of Participants Achieving Endoscopic Remission Measured by Modified Baron Score.
Prazo: Up to 18 months (as available from routine clinical care)

Proportion of participants achieving endoscopic remission assessed using validated endoscopic scoring systems:

Modified Baron Score (ulcerative colitis) (range 0-4), where lower scores indicate less mucosal inflammation and endoscopic remission is defined as a score of 0 (normal mucosa with no visible inflammation)

Endoscopic findings are collected as part of routine clinical care, when available.

Up to 18 months (as available from routine clinical care)
Treatment Persistence
Prazo: Up to 18 months

Duration of time from treatment initiation to discontinuation of index therapy for any reason, including continued use at pre-specified timepoints.

Up to 18 months
Proportion of Patients with Dose Escalation
Prazo: Up to 18 months

Proportion of patients who discontinue index therapy and/or initiate a subsequent IBD therapy during the study period.

Up to 18 months
Time to Next Treatment
Prazo: Up to 18 months

Time from initiation of index therapy to initiation of a subsequent therapy or discontinuation of index therapy.

Up to 18 months
Concomitant Medication Use
Prazo: Baseline through 18 months

Proportion of patients receiving concomitant corticosteroids, immunomodulators, or aminosalicylates at baseline and during follow-up, including initiation and discontinuation patterns.

Baseline through 18 months
Corticosteroid-Free Time
Prazo: Up to 18 months

Duration of time patients remain free from corticosteroid use while receiving index therapy.

Up to 18 months
Healthcare Resource Utilization
Prazo: Up to 18 months

Frequency and rate of IBD-related healthcare utilization

Up to 18 months
Change in Patient-Reported Outcomes Measured by SIBDQ
Prazo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in patient-reported outcomes assessed using validated instrument:

Short Inflammatory Bowel Disease Questionnaire (SIBDQ) (range 10-70), where higher scores indicate better health-related quality of life

Changes in scores over time will be evaluated to assess symptom burden, quality of life, and functional outcomes.

Baseline, 6 months, 12 months, and 18 months
Change in Patient-Reported Outcomes Measured by UNRS
Prazo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in patient-reported outcomes assessed using validated instrument:

Bowel Urgency Numeric Rating Scale (UNRS) (range 0-10), where higher scores indicate worse bowel urgency

Changes in score over time will be evaluated to assess symptom burden, quality of life, and functional outcomes.

Baseline, 6 months, 12 months, and 18 months
Change in Patient-Reported Outcomes Measured by PROMIS Global Health
Prazo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in patient-reported outcomes assessed using validated instrument:

PROMIS Global Health (PROMIS-GH) (T-score standardized, mean 50), where higher scores indicate better overall health status

Changes in score over time will be evaluated to assess symptom burden, quality of life, and functional outcomes.

Baseline, 6 months, 12 months, and 18 months
Change in Patient-Reported Outcomes Measured by SAA
Prazo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in patient-reported outcomes assessed using validated instrument:

Sexual Activity Avoidance (SAA), where higher scores indicate greater avoidance of sexual activity

Changes in scores over time will be evaluated to assess symptom burden, quality of life, and functional outcomes.

Baseline, 6 months, 12 months, and 18 months
Change in Patient-Reported Outcomes Measured by WPAI:SHP
Prazo: Baseline, 6 months, 12 months, and 18 months

Change from baseline in patient-reported outcomes assessed using validated instrumens:

Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) (0-100%), where higher percentages indicate greater impairment

Changes in score over time will be evaluated to assess symptom burden, quality of life, and functional outcomes.

Baseline, 6 months, 12 months, and 18 months
Proportion of Participants Achieving Clinical Remission Based on Ulcerative Colitis PRO2.
Prazo: Baseline, 6 months, 12 months, and 18 months

Proportion of participants achieving clinical remission based on validated patient-reported outcome measures:

Ulcerative Colitis Patient-Reported Outcome 2 (UC PRO2), composed of:

Stool frequency score (range 0-3) Rectal bleeding score (range 0-3) Lower scores indicate less disease activity; clinical remission is defined as rectal bleeding score = 0 and stool frequency score ≤1

These thresholds represent minimal or no symptoms consistent with clinical remission.

Baseline, 6 months, 12 months, and 18 months
Proportion of Participants Achieving Clinical Remission Based on Crohn's Disease PRO2.
Prazo: Baseline, 6 months, 12 months, and 18 months

Proportion of participants achieving clinical remission based on validated patient-reported outcome measures: Crohn's Disease Patient-Reported Outcome 2 (UC PRO2), composed of: Stool frequency score (range 0-3) Rectal bleeding score (range 0-3) Lower scores indicate less disease activity; clinical remission is defined as rectal bleeding score = 0 and stool frequency score ≤1 These thresholds represent minimal or no symptoms consistent with clinical remission.

Baseline, 6 months, 12 months, and 18 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Casey Chapman, MD, GIA
  • Investigador principal: Nicholas Lazarou, MPH, MBA, Cardinal Health

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

12 de agosto de 2026

Conclusão Primária (Estimado)

1 de junho de 2028

Conclusão do estudo (Estimado)

1 de junho de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

18 de junho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

29 de junho de 2026

Primeira postagem (Real)

7 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

29 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 103899

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

This study does not plan to share Individual Participant Data (IPD)

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .